PlaqueTec, a medtech company focused on intracoronary liquid biopsy technology, announced the close of a $5 million financing round to advance its cardiovascular disease data platform and research capabilities.
The oversubscribed round was fully backed by existing shareholders, signaling continued investor confidence in the company’s approach to identifying inflammatory drivers of cardiovascular disease. The funding will be used to expand PlaqueTec’s proprietary data platform, BioCarta, which aggregates intracoronary proteomic and clinical data to improve disease understanding and treatment strategies.
BioCarta is designed as a high-resolution cardiovascular data lake that captures biomarkers directly at the site of plaque formation, offering insights that traditional blood sampling methods cannot provide. The platform supports a site-of-disease approach to better stratify patient risk and guide targeted therapeutic development, with the potential to improve outcomes in coronary artery disease.
The company’s data is generated through its BIOPATTERN trial, which collects proteomic samples using PlaqueTec’s intracoronary liquid biopsy technology. By analyzing coronary concentration gradients, the platform identifies biomarkers linked to inflammation and disease progression, enabling more precise patient segmentation and treatment pathways.
PlaqueTec has already identified several potential therapeutic targets within subgroups of coronary artery disease patients, positioning its dataset as a valuable resource for pharmaceutical and biotech companies. The company is currently engaged in discussions with potential partners interested in leveraging its data for drug development and patient stratification.
The funding will support continued data collection, platform development, and partnership efforts as PlaqueTec works to establish BioCarta as a foundational asset in cardiovascular research and precision medicine.
KEY QUOTE:
“The decision by our existing shareholders to reinvest, and to do so at a level that exceeded our target, speaks directly to their confidence in what PlaqueTec’s data is revealing about cardiovascular disease. We are building something genuinely differentiated: a high-resolution, intracoronary data asset that is poised to underpin the next generation of cardiovascular therapeutics. This round validates that strategy and gives us the runway to prove it.”
Martin Stapleton, Chairman, PlaqueTec
